Why the study?
Does local instillation of mitomycin C improve remission of malignant pericardial effusion in patients with advanced non-small cell lung cancer?
Does local instillation of mitomycin C improve remission of malignant pericardial effusion in patients with advanced non-small cell lung cancer?
Intrapericardial instillation of mitomycin C is a feasible and potentially effective strategy for managing malignant pericardial effusion in non-small cell lung cancer.
Supports feasibility of intrapericardial mitomycin C in NSCLC; leaves open need for controlled trials before practice change.
BACKGROUND: To evaluate the clinical efficacy and safety of mitomycin C in the local control of malignant pericardial effusion, we carried out a trial of pericardial drainage with local instillation of mitomycin C in eight patients who suffered from cardiac tamponade or symptomatic large pericardial effusion caused by advanced non-small cell lung cancer. METHODS: After complete removal of the pericardial effusion by an ultrasound-guided inserted catheter, 2 mg of mitomycin C was instilled into the pericardial space via the catheter. RESULTS: The drainage catheter was successfully removed in all patients. The duration of pericardial drainage ranged from 7 to 14 days (median 10.5 days). Six of the eight patients achieved a complete remission of pericardial effusions without any adverse effects. CONCLUSION: Intrapericardial instillation of 2 mg of mitomycin C was feasible and demonstrated a promising response against malignant pericardial effusion resulting from non-small cell lung cancer.
No takes yet. Share an insight, caveat, or question.
Kyoichi Kaira (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: